Huminsulin R 100 IU Injection 3 ml Cartridge

Humininsulin R 100 IU Injection 3ml cartridge is used to treat type 1 and type 2 diabetic mellitus. It is a metabolic disease in which blood glucose concentrations are persistently elevated. The medicine contains an active drug Human insulin (100IU), which belongs to the group of anti diabetic agents, specifically short-acting insulin (regular insulin).

It works by facilitating the uptake of glucose into muscle and adipose tissues, inhibiting hepatic glucose production, and thereby lowering blood glucose levels. A prescription from a healthcare provider is required before using the medication.

• Manage blood glucose level

Every medication has several side effects that may occur depending on the dose, duration and individual patient response. Consult the doctor If any of the symptoms persist while using Humininsulin R Injection:

• Low blood sugar (Hypoglycaemia)
• Lightheadedness
• Dizziness
• Anxiety
• Nervousness
• Tiredness
• Feeling hungry
• Visual disturbances
• Headache
• Shaking
• Sweating
• Pale skin
• Skin rashes
• Pain, redness, swelling at the injection site.

Doctors prescribed Humininsulin R Injection before or after taking the food. The injection is given by a doctor or nurse in the abdomen, upper arms, and buttocks, ensuring proper absorption and effective control of the blood sugar level. Never skip or overdose on the medication without taking proper consultation with a healthcare professional.

Blood sugar levels are regulated by hormones like insulin, but when it is deficient and does not function properly, glucose accumulates in the blood, leading to diabetes mellitus. Humininsulin R Injection helps to replace the deficient insulin and maintain normal blood sugar glucose level by promoting glucose uptake into cells and reducing glucose production by the liver.

• Jørgensen, K. H., Hansen, A. K., & Buschard, K. (2000). Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes research and clinical practice, 50(3), 161-167.  https://pubmed.ncbi.nlm.nih.gov/11106830/
• Owens, D. R. (1986). Human insulin: clinical pharmacological studies in normal man. Springer Science & Business Media. https://catalog.nlm.nih.gov/discovery/fulldisplay?docid=alma996129413406676&context=L&vid=01NLM_INST:01NLM_INST&lang=en&adaptor=Local%20Search%20Engine&tab=LibraryCatalog&query=lds56%2Ccontains%2CClinical%20Trials%20as%20Topic%2CAND&mode=advanced&offset=130
• CHRISTIANSEN, J. S., SONNENBERG, G. E., KVERNELAND, A., SCHMITZ, A., CHRISTENSEN, C. K., HERMANSEN, K., ... & DECKERT, T. (1987). Clinical Outcome of Using Insulin at 40 IU/ml and 100 IU/ml in Pump Treatment: Results of a Controlled Multi‐Center Trial. Acta Medica Scandinavica, 222(1), 65-70. https://pubmed.ncbi.nlm.nih.gov/3307309/
• Chien, Y. W. (1996). Human insulin: basic sciences to therapeutic uses. Drug development and industrial pharmacy, 22(8), 753-789. https://pubmed.ncbi.nlm.nih.gov/3523470/
• Boehm, B. O., Home, P. D., Behrend, C., Kamp, N. M., & Lindholm, A. (2002). Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabetic Medicine, 19(5), 393-399. https://pubmed.ncbi.nlm.nih.gov/12027927/